Therapy Areas: Central Nervous System
Lunai Bioworks completes USD20m preferred issuance to acquire CNS delivery and neurotherapeutic IP
5 May 2026 - US life sciences company Lunai Bioworks Inc (NASDAQ:LNAI) announced on Monday the completion of a USD20m preferred equity issuance to acquire intellectual property assets from two counter...
Solvonis Therapeutics appoints Water Tower Research to strengthen US market positioning
22 April 2026 - Biopharmaceutical company Solvonis Therapeutics plc (LSE: SVNS) announced on Wednesday that it has appointed US-based research and investor engagement firm Water Tower Research LLC to ...
Solvonis Therapeutics secures second US patent for PTSD compound series
8 April 2026 - Solvonis Therapeutics plc (LSE: SVNS), a biopharmaceutical company developing small-molecule treatments for central nervous system disorders, announced on Wednesday that it has been gra...
Insilico Medicine and Tenacia expand AI-driven R&D collaboration
27 March 2026 - Insilico Medicine (HK:3696), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, and Tenacia Biotechnology (Hong Kong) Co Limited, a China-based, com...
TheraCryf advances lead addiction programme to final preclinical stage
23 March 2026 - TheraCryf plc (AIM: TCF), a UK-based biotech company that develops new medicines for addiction and other neuropsychiatric disorders, announced on Monday that it has completed preclinic...
Collegium to acquire AZSTARYS from Corium Therapeutics
20 March 2026 - Collegium Pharmaceutical Inc (Nasdaq:COLL) and Corium Therapeutics Holdings LLC announced on Thursday a definitive agreement for Collegium to acquire AZSTARYS for USD650m in cash with ...